AzurRx BioPharma's clinical trial hits midway point & more — 3 GI company key notes

Here are three updates on GI companies from the past week:

Boehringer Ingelheim Pharmaceuticals's Cyltezo, a second biosimilar for AbbVie's Humira, received FDA approval.

AzurRx BioPharma enrolled a sixth patient into its phase IIa trial for MS1819, a treatment for exocrine pancreatic insufficiency associated with chronic pancreatitis.

4D Pharma is preparing to move its irritable bowel syndrome drug, Blautix, into a phase II clinical trial.

More articles on gastroenterology: 
Stock market week-in-review for 5 large GI companies — Aug. 21-25
GI center to know: Associated Endoscopy
GI leader to know: Dr. G. Whit James of Associates in Gastroenterology

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers